Trials / Recruiting
RecruitingNCT05354765
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Institut Curie · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | blood sample | lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression |
| OTHER | blood sample | lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment |
Timeline
- Start date
- 2022-08-31
- Primary completion
- 2026-09-03
- Completion
- 2026-09-03
- First posted
- 2022-04-29
- Last updated
- 2025-01-24
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05354765. Inclusion in this directory is not an endorsement.